Osiris Therapeutics Says Trial on Grafix Met All Primary, Secondary Endpoints

Osiris Therapeutics, Inc. (NASDAQ: OSIR ), the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that Dr. Matthew Regulski, Medical Director of the Wound Institute of New Jersey, will present clinical trial data, including secondary endpoints, from Osiris' multi-center, randomized, controlled clinical trial